In front of the U.S. House Ways and Means Subcommittee, Dr. Edgerton described how challenges of biosimilar costs threaten patient care and outlined several potential legislative solutions.
The ACR’s delegation to the American Medical Association House of Delegates is seeking ACR members who may be interested in serving as representatives to the Young Physician Section.
Changes announced April 1 will cut 10,000 positions at the U.S. Department of Health & Human Services and consolidate many department functions. The ACR is monitoring how these changes may impact regulatory issues of concern to ACR members.
This May, more than 120 ACR leaders, fellows and patients with rheumatic disease will converge in Washington, D.C., to lobby Congress on issues including protecting Medicare and Medicaid, National Institutes of Health research funding and pharmacy benefit manager reform.
With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.
With Mehmet Oz, MD, expected to be confirmed as administrator of the Centers for Medicare & Medicaid Services, the ACR considers how his stated priorities may affect rheumatology.
Three bills centering reintroduced in the 119th Congress would ease educational debt burden, increase placement access for visa holders and support the mental health of current healthcare workers.
This annual event, to be held May 4–6, brings together the rheumatology community to advocate on Capitol Hill for the profession and rheumatic disease patients.
Medicare’s current telehealth flexibilities are set to expire March 31. To avoid a government shutdown, Congress must pass a appropriations package by midnight on March 14. The ACR is preparing for the impacts if a telehealth extension does not pass.
These events will provide a critical opportunity for patients, caregivers, patient organizations, clinicians and researchers to offer input on the drugs selected for the second cycle of negotiations.